• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    10/28/24 4:02:11 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    SC 13G/A 1 rosalind_nspr_13ga_5_sep.htm Schedule 13G

     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A
    (Amendment No. 5)

    Under the Securities Exchange Act of 1934

    InspireMD, Inc.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    45779A846

    (CUSIP Number)

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ¨  Rule 13d-1(b)
    x  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     

    NYC#: 139632.2


     


     

     

     

     

     

     

    CUSIP No. 45779A846

     

    13G/A

     

    Page 2 of 10 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Advisors, Inc.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER  
     0

     

    6.

     

    SHARED VOTING POWER
     
    2,514,046 shares of Common Stock

    7,438,181 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    2,514,046 shares of Common Stock

    7,438,181 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,514,046 shares of Common Stock

    7,438,181 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.8%1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     

     


    1 This percentage is calculated based upon 25,706,671 shares of common stock outstanding of the Issuer as of August 05, 2024, in accordance with Issuer’s 10-Q filed on August 05, 2024. However, as more fully described in Item 3, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (8), (10) and (11).


     

    NYC#: 139632.2


     


    CUSIP No. 45779A846

     

    13G/A

     

    Page 3 of 10 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Steven Salamon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    2,514,046 shares of Common Stock

    7,438,181 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    2,514,046 shares of Common Stock

    7,438,181 Shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,514,046 shares of Common Stock

    7,438,181 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.8%1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     

     

     

     

     

     

     

     

     

     

     


     

    NYC#: 139632.2


     


    CUSIP No. 45779A846

     

    13G/A

     

    Page 4 of 10 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Gilad Aharon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    2,514,046 shares of Common Stock

    7,438,181 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
     2,514,046 shares of Common Stock

     7,438,181 Shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,514,046 shares of Common Stock

    7,438,181 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.8%1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     

     

     

     

     

     

     

     

     

     

     


     

    NYC#: 139632.2


     


    CUSIP No. 45779A846

     

    13G/A

     

    Page 5 of 10 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Master Fund L.P.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    1,962,046 shares of Common Stock

    6,334,181 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    1,962,046 shares of Common Stock

    6,334,181 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,962,046 shares of Common Stock

    6,334,181 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)  ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.6%1 above

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

     

     

     

     

     


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. 45779A846

     

    13G/A

     

    Page 6 of 10 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Opportunities Fund I L.P.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
    0

     

    6.

     

    SHARED VOTING POWER
     

    552,000 shares of Common Stock

    1,104,000 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     0

     

    8.

     

    SHARED DISPOSITIVE POWER
     

    552,000 shares of Common Stock

    1,104,000 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    552,000 shares of Common Stock

    1,104,000 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)  ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.2%1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

     

     

     

     

     


     

    NYC#: 139632.2


     


     

     

     

     

     

     

    CUSIP No. 45779A846

     

    13G/A

     

    Page 7 of 10 Pages

     

     

     

     

     

    Item 1.

     

    (a)

    Name of Issuer: InspireMD, INC.

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices
    4 MENORAT HAMAOR. ST., Tel Aviv, Israel 6744832

     

     

     

    Item 2.

     

    (a)

    Name of Person Filing

    Rosalind Advisors, Inc. (“Advisor” to RMF and ROFI)

    Rosalind Master Fund L.P. (“RMF”)

    Rosalind Opportunities Fund I L.P. (“ROFI”)

    Steven Salamon (“President”)

    Steven Salamon is the portfolio manager of the Advisor which advises RMF.

    Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.

     

     

     

     

     

    (b)

    Address of the Principal Office or, if none, residence
    Rosalind Advisors, Inc.

    Rosalind Opportunities Fund I L.P.

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Rosalind Master Fund L.P.

    P.O. Box 309

    Ugland House, Grand Cayman

    KY1-1104, Cayman Islands

     

    Steven Salamon

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Gilad Aharon

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

     

     

     

    (c)

    The principal business of Rosalind Advisors, Inc. is to operate as an investment advisory firm and to make public equity investments. The principal occupation of Mr. Salamon is serving as the Portfolio Manager and President of Rosalind Advisors, Inc., which advises Rosalind Master Fund L.P. and Rosalind Opportunities Fund I L.P.

     

     

     

     

    (d)

    No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

     

     

     

    (e)

    No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

     

     

     

    (f)

    Mr. Salamon and Mr. Aharon are citizens of Canada, resident in Ontario


     

    NYC#: 139632.2


     


    CUSIP No. 45779A846

     

    13G/A

     

    Page 8 of 10 Pages

     

     

     

     

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)

    ¨

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

     

     

     

     

    (b)

    ¨

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (c)

    ¨

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (d)

    ¨

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

     

     

     

     

    (e)

    ¨

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    (f)

    ¨

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ¨

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

     

     

     

     

    (h)

    ¨

    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

     

    (i)

    ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

     

     

     

     

    (j)

    ¨

    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    Item 4.  Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

     

     

     

     

    (a)

     

    Amount beneficially owned:  

     

    The information as of the date of the event which requires filing of this statement required by Items 5(a) – (c) is set forth in Rows 7 – 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 13 of the cover page for each Reporting Person is based upon 25,706,671 shares of common stock outstanding of the Issuer as of August 05, 2024, in accordance with Issuer’s 10-Q filed on August 05, 2024.

    Rosalind Master Fund L.P. is the record owner of 1,962,046 shares of common stock. .

    Rosalind Advisors, Inc., or the Advisor, is the investment advisor to RMF and ROFI, and may be deemed to be the beneficial owner of shares held by RMF and ROFI. Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF and ROFI.  Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.  

     

     

     

     

     

     

    (b)

     

    Percent of class:  

    Rosalind Advisors, Inc. –  9.8%

    Rosalind Master Fund L.P. –  7.6%

    Rosalind Opportunities Fund I L.P. – 2.2%

    Steven Salamon –  9.8%

    Gilad Aharon –  9.8%


     

    NYC#: 139632.2


     


     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

    NYC#: 139632.2


     


    CUSIP No. 45779A846

     

       

                                                    13G/A

    Page 9 of 10 Pages

     

     

     

     

     

     

    (c)

     

    Number of shares as to which the person has:  

     

     

     

    (i)

    Shared power to vote or to direct the vote  

    Rosalind Advisors, Inc. –  2,514,046

    Rosalind Master Fund L.P. –  1,962,046

    Rosalind Opportunities Fund I L.P. – 552,000

    Steven Salamon – 2,514,046

    Gilad Aharon - 2,514,046

     

     

     

     

     

     

     

     

    (ii)

    Sole power to dispose or to direct the disposition of  – 0

     

     

     

     

     

     

     

     

    (iii)

    Shared power to dispose or to direct the disposition of  

    Rosalind Advisors, Inc. –  2,514,046

    Rosalind Master Fund L.P. –  1,962,046

    Rosalind Opportunities Fund I L.P. – 552,000

    Steven Salamon –  2,514,046

    Gilad Aharon - 2,514,046

     

     

     

     

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

    Instruction. Dissolution of a group requires a response to this item.

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    Item 7 – 9.  Not Applicable


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. 45779A846

     

    13G

     

    Page 10 of 10 Pages

     

     

     

     

     

    Item 10.  Certification.

     

     

     

     

     

     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    10/28/2024

    Date

     

    s/s Steven Salamon

    Signature

     

    Steven Salamon/President Rosalind Advisors, Inc.

    Name/Title

     

     

    Exhibit A

    Joint Filing Agreement

     

    The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of InspireMD, Inc. is filed jointly, on behalf of each of them.

     

     

    Rosalind Advisors, Inc.

    By: _____________________________

    Name: Steven Salamon

    Title: President

     

    Rosalind Master Fund L.P.

    By: _____________________________

    Name: Mike McDonald

    Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

     

    By: _____________________________

    Name: Steven Salamon

     

    Rosalind Opportunities Fund I L.P.

     

    By: _____________________________

    Name: Steven Salamon

    Title: Director, Rosalind Opportunities Fund I GP. Inc. (as General Partners to Rosalind Opportunities Fund I)


     

    NYC#: 139632.2

    Get the next $NSPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NSPR
    SEC Filings

    See more
    • InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - InspireMD, Inc. (0001433607) (Filer)

      5/9/25 7:09:33 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by InspireMD Inc.

      10-Q - InspireMD, Inc. (0001433607) (Filer)

      5/8/25 4:05:21 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by InspireMD Inc.

      DEFA14A - InspireMD, Inc. (0001433607) (Filer)

      4/16/25 4:05:25 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InspireMD Reports First Quarter 2025 Financial Results

      MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launchContinued enrollment with excellent pace in the CGUARD

      5/9/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

      MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the Bank of America 2025 Healthcare Conference on Wednesday, May 14, 2025, at 1:15PM Eastern Time / 10:15AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 90 days on the "News & Events" section of the company's website at: https://www.inspiremd.com/en/events/ About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by pro

      4/30/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD to Announce First Quarter 2025 Financial Results

      MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by

      4/25/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    See more
    • InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

      MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE:ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his

      11/25/24 4:05:00 PM ET
      $ABT
      $NSPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

      TEL AVIV, Israel and MIAMI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that the Company has appointed principal investigators (PIs) for its upcoming C-GUARDIANS II clinical trial of the SwitchGuard™ Neuroprotection System (NPS). Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, have enthusiastically agreed to act as lead PIs for the trial.

      2/12/24 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

      Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team Reports inducement grant under NASDAQ listing rule 5635(c)(4) TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America. Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team. Marvin Slosman, Chief Executive Officer of InspireMD

      1/3/24 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Tommasoli Andrea was granted 232,616 shares, increasing direct ownership by 47% to 727,694 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:33 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Director Berman Michael was granted 32,491 shares, increasing direct ownership by 14% to 264,533 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:18 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • CEO and President Slosman Marvin was granted 558,417 units of Restricted Stock Units, increasing direct ownership by 30% to 2,410,536 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:26 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Financials

    Live finance-specific insights

    See more
    • InspireMD Reports First Quarter 2025 Financial Results

      MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launchContinued enrollment with excellent pace in the CGUARD

      5/9/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD to Announce First Quarter 2025 Financial Results

      MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by

      4/25/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

      MIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. ahead of an anticipated first half 2025 approvalAnnounced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use du

      3/12/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by InspireMD Inc.

      SC 13G - InspireMD, Inc. (0001433607) (Subject)

      12/4/24 4:31:06 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

      SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

      11/14/24 6:35:20 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

      SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

      10/28/24 4:02:11 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Roubin Gary S bought $126,540 worth of shares (50,000 units at $2.53), increasing direct ownership by 13% to 438,902 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      12/4/23 4:15:25 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care